Months after FDA rejection, Sanofi touts pivotal win for rare disease drug sutimlimab as it preps to refile
One of the pillar drugs of Sanofi’s $11.6 billion pickup of Bioverativ hit a big setback late last year when the FDA sent its application for approval back. Now, as Sanofi gears up to resubmit the drug for review, the drugmaker is touting pivotal data it hopes will help take it over the finish line.
Sanofi’s sutimlimab nailed all three of its primary endpoints in its Phase III CADENZA study for patients with cold agglutinin disease, a rare disorder that can cause severe anemia, without a recent history of blood transfusion, the French drugmaker said Friday. The topline results will be presented at this weekend’s virtual EHA meeting.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.